Company news

Savara, Inc. news in 2022

Savara, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

November 9, 2022

Savara to Participate in Three Upcoming Investor Conferences

November 8, 2022

Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022

September 5, 2022

Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference

August 31, 2022

Savara Announces Resignation of Chief Medical Officer

August 25, 2022

Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

August 24, 2022

Savara Reports Second Quarter 2022 Financial Results and Provides Business Update

August 10, 2022

Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022

July 10, 2022

Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic

June 15, 2022

Savara to Present at Jefferies Healthcare Conference

May 31, 2022

Savara to Present at H.C. Wainwright Global Investment Conference

May 16, 2022

Savara Reports First Quarter 2022 Financial Results and Provides Business Update

May 10, 2022

Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank

April 21, 2022

Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update

March 29, 2022

Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference

March 8, 2022

Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

January 3, 2022

Decks in 2022